Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Myeloid cell-mediated killing of BCP-ALL by IgA2 variants of CD38 or CD20 antibodies is enhanced by CD47/SIRPα interference

ABSTRACT: Characterization of therapeutic monoclonal antibodies used in the context of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). IgA2 antibodies targeting CD38 were analyzed using LC-MS/MS. Mass analysis, peptide mapping and glycoprofiling were performed to confirm sequence integrity and post-translational modifications. The analysis supports preclinical evaluation of antibody-based immunotherapies and provides insights into glycosylation relevant for effector function.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Blood

DISEASE(S): Acute Leukemia

SUBMITTER: Arturo Macarron Palacios

LAB HEAD: Arturo Macarrón Palacios

PROVIDER: PXD066660 | Pride | 2026-06-09

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	INtact_ResultsAT.bin	Other
	IndexedLcMsData.bin	Other
	Intact_Autotune.tun	Other
	Intact_BinPump1.cd	Other
	Intact_BinPump1.cg	Other

Items per page:

1 - 5 of 51

Similar Datasets

Chemical Targeting of the Redox Switch in the Transcription Factor ΔFOSB

Project description:Purified protein fragments (~8 kDa bZIP domains, ΔFOSB and JunD) were reacted with individual compounds selected from a previous library screen. Reacted proteins were analyzed by LC-MS/MS peptide mapping and LC-MS intact mass analysis.

2022-10-14 | PXD035839 | Pride

Dilute-and-Shoot Analysis of Therapeutic Monoclonal Antibody Variants in Fermentation Broth: A Method Capability Study

Project description:Monoclonal antibodies (mAbs) are widely applied as highly specific and efficient thera-peutic agents for various diseases, including cancer, inflammatory and autoimmune diseases. As protein production in cellular systems inherently generates a multitude of molecular variants, manufacturing of mAbs requires stringent control in order to ensure safety and efficacy of the drug. Moreover, monitoring of mAb variants in the course of the fermentation process may allow instant tuning of process parameters to maintain optimal cell culture conditions. Here, we describe a fast and robust workflow for the characterization of mAb variants in fermentation broth. Sample preparation is minimal in that the fermentation broth is shortly centrifuged before dilution and HPLC-MS analysis in a short 15-min gradient run. In a single analysis, N-glycosylation and truncation variants of the expressed mAb can be identified at the intact protein level. The molecular attributes of the expressed therapeutic protein may thus be continuously monitored to ensure the desired product profile. Simultaneously, absolute quantification of mAb content in fermentation broth yielded concentrations of 67 and 2578 ng.mL-1 at the beginning and end of fermentation, respectively. The whole workflow features excellent robustness as well as retention time and peak area stability of 0.3% and 4.9% RSD. Additional enzymatic removal of N-glycans enables determination of mAb glycation levels, which are subsequently considered in relative N-glycoform quantification to correct for isobaric galactosylation. Application of the described workflow in an industrial environment may therefore substantially enhance in-process control in mAb production as well as targeted biosimilar development.

2019-11-12 | PXD011017 | Pride

Multi-level – Intact, Subunits, and Peptides – Characterization of Antibody-Based Therapeutics by a Single-Column LC-MS setup

Project description:A comprehensive characterization of biotherapeutics, mandated by regulatory authorities, require analyses of a protein drug at multiple structure levels. Such multi-level characterization can be performed by mass spectrometry (MS), with established conventional MS-based assays of product quality attributes (PQAs) comprising intact protein and subunit middle-up MS with analytes resolved on a C4 column, and bottom-up peptide mapping with analytes resolved on C18 column. Recent advances in MS have facilitated the increasing use of middle-down analysis, expanding the qualitative analytical capability of MS for protein characterization. Recent studies using less retentive reversed-phase LC in bottom-up MS also offer an opportunity for streamlining equipment configuration to a single-column LC-MS setup for multi-level characterization of therapeutic pro-teins. In this study, we developed a robust middle-down LC-MS method on a ZenoTOF 7600, and evaluated a C4 LC-MS setup for the characterization of NISTmAb, RG7221 bispecific antibody (bsAb) and Fc-fusion etanercept by intact protein, subunit middle-up/down and bottom-up analyses. Successful multi-level characterization of the analytes using C4 LC-MS was demonstrated; notably, high sequence coverage and comprehensive PTMs profiling, including the mapping of all 13 O- and 3 N-glycosylation sites on etanercept in a single run, were obtained by bottom-up C4 LC-MS. This is also the first report on middle-down analysis of the major etanercept TNFR and Fc subunit glycoforms. A streamlined single-column LC-MS setup will enable more robust and efficient MS workflows for PQAs assessment and simplify the integration of LC-MS analyzer as a Process Analytical Technology (PAT) instrument for biopharma applications.

2025-02-26 | PXD054948 | Pride

Gene profiling of the early healing rat medial collateral ligament

Project description:The objective of the study was to better understand the mechanism behind scar formation by identifying ECM factors and other unique genes differentially expressed during rat ligament healing via microarray. Rat medial collateral ligaments (MCL) were surgically transected or left intact. MCLs were collected at day 3 or 7 post-injury and used for microarray analysis. Results were compared to the normal intact ligaments. A total of 27 rats were used in the study. Animals were randomly placed in 1 of 3 groups (day 3, day 7, intact CX) with nine animals included with each time (9 rats/group). At the time of collection, MCLs from each time were placed into 3 pools (3 MCLs/pool), resulting in 3 reps per time, and usd for microarray analysis. A total of 9 gene chips were used for the experiment (3 chips/day).

2013-06-06 | E-GEOD-47676 | biostudies-arrayexpress

A Novel Mechanism Mediated by Allosteric Disulfide Bonds Fine-Tunes Thrombus Formation

Project description:Mapping of disulfide bonds and quantification of their redox state in the human histidine rich glycoprotein

2024-04-11 | PXD050718 | Pride

Anti-sense oligonucleotide inhibited iSAT reaction

Project description:Investigating the intricate and rapid folding kinetics of large RNA-protein complexes (RNPs), like the bacterial ribosome, remains a formidable challenge in structural biology. Previous genetic approaches to probe assembly have focused on modulating the expression of either r-proteins or assembly factors. Here, anti-sense oligonucleotides (ASOs) were used to disrupt native RNA/RNA and RNA/protein interactions, in order to generate previously uncharacterized folding intermediates. In an in vitro co-transcriptional ribosome assembly assay, 10 assembly inhibitor ASOs were identified. Using cryo-electron microscopy, 38 intermediate structures were determined resulting from the specific inhibitions generated by 6 inhibitory ASOs. A notable intermediate class provided compelling evidence for independent rRNA domain folding before proper interdomain docking. Three PNAs targeting domain-I of 23S rRNA further subdivided the previously identified assembly core into smaller blocks representing the earliest steps in assembly. The resulting assembly graph reveals template-directed RNA docking of defined regions as foldons, and domain consolidation, which provides a hierarchical view of the RNP assembly process. This approach not only identified potential targets for antibiotic development but also established a platform for probing the structure and dynamics of RNP assemblies.

2025-07-28 | PXD064127 | Pride

Analysis and design of RNA sequencing experiments for identifying mRNA isoform regulation

Project description:Through alternative splicing, most human genes express multiple isoforms that may have distinct or even antagonistic functions. To infer isoform regulation based on data from high-throughput sequencing of cDNA fragments (RNA-Seq), we have developed MISO, a computational model that estimates the expression level of alternatively spliced exons and mRNA isoforms and provides intuitive measures of con?dence in these estimates. Incorporation of the length distribution of inserted cDNA fragments in paired-end RNA-Seq analysis in MISO enables dramatic improvements in estimation of alternative splicing levels relative to previous methods. We show that one lane of paired-end RNA-Seq data can provide far more information about splicing than two lanes of single-end data, depending critically on properties of the distribution of cDNA fragment lengths in the sequenced library. MISO also leads to an intuitive method to detect di?erentially regulated exons or isoforms. Application of this method implicates the RNA splicing factor hnRNP H in regulation of alternative cleavage and polyadenylation, a role that is supported by UV crosslinking/immunoprecipitation/high-throughput sequencing (CLIP-Seq) analysis. Together, our results provide a probabilistic framework for RNA-Seq analysis, derive functional insights into pre-mRNA processing, and yield guidelines for the optimal design of RNA-Seq experiments for studies of gene and isoform expression. CLIPseq of hnRNP H in HEK 293T cells. RNAseq of polyA+ RNA from C2C12 mouse myoblasts stably expressing an empty vector or a vector containing an shRNA against CUGBP1. Libraries of two different insert lengths were created and examined.

2010-11-07 | E-GEOD-23694 | biostudies-arrayexpress

Gene expression profile at single cell level of vessel associated kidney NKp46+ ILC from healthy and nephritic NZB/W lupus prone mice

Project description:Kidney vessel associated NKp46+ ILC have never been characterized at single cell level before. We used single cell RNA sequencing (scRNA-seq) to analyze the diversity of kidney vessel associated NKp46+ ILC in the kidney

2026-03-04 | E-MTAB-16156 | biostudies-arrayexpress

De Novo Sequencing of Polyclonal Antibodies by Integrating Intact Mass, Top-Down and Bottom-Up Mass Spectrometry

Project description:Antibodies are specialized proteins produced by the adaptive immune system to identify and neutralize harmful antigens. Antibody-based diagnostics and therapeutics have advanced rapidly, with recombinant antibodies derived from monoclonal antibodies (mAbs) becoming the preferred standard due to their high reproducibility and effectiveness. However, mAbs are limited to binding a single antigen epitope. Polyclonal antibodies (pAbs), on the other hand, are produced by multiple B cells and can target multiple epitopes, making them more robust against antigen variations. Despite their advantages, pAbs are notoriously challenging to sequence due to their high complexity. Current de novo sequencing methods based on mass spectrometry have shown limitations when applied to pAb mixtures, often requiring germline databases or yielding incomplete or inaccurate sequences. Here we propose PolySeq, a fully de novo sequencing workflow that integrates bottom-up, top-down, and intact mass spectrometry data to accurately sequence pAb samples without relying on external databases. Our workflow automates the entire sequencing process from peptides to full proteins, achieving complete and accurate antibody profiles. Evaluation results on a mixture of four known mAbs and a pAb sample derived from mouse myeloma demonstrate that our de novo antibody sequences achieved up to 100% coverage and accuracy, with strong supporting evidence from bottom-up, top-down, and intact mass data. Furthermore, antibodies recombinantly expressed using de novo sequencing results showed expected properties, such as binding affinity and antigen neutralization, thus confirming the accuracy and efficacy of our pAb de novo sequencing workflow.

2025-10-31 | PXD063526 | Pride

ProSight Native Complex Down Analysis of Aquaporin Z

Project description:In this dataset, we analyzed Aquaporin Z using native mass spectrometry. The data was then input into ProSight Native to determine the protein complex composition.

2023-08-14 | PXD038817 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data